Simridarlimab

(Synonyms: IBI-322)
Revisión del cliente

Based on 1 Customer Validation

Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.81%
  • No. CAS: 2378862-90-7
  • Peso molecular:125.734 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00